Kezar Life Sciences Inc (KZR)
$7.5
Performance
- $7.41$7.60$7.50
1.27%
Downside
Day's Volatility :2.57%
Upside
1.32%
- $5.20$11.35$7.50
30.64%
Downside
52 Weeks Volatility :54.17%
Upside
33.92%
Returns
| Period | Kezar Life Sciences Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 19.29% | -7.3% | 0.0% |
6 Months | 2.94% | -0.5% | 0.0% |
1 Year | -18.01% | 10.5% | 0.0% |
3 Years | -94.31% | 8.8% | -24.0% |
Highlights
Market Capitalization | 55.6M |
Book Value | $25.77 |
Earnings Per Share (EPS) | -13.12 |
Wall Street Target Price | 14.5 |
Profit Margin | 0.0% |
Operating Margin TTM | -1422.01% |
Return On Assets TTM | -28.07% |
Return On Equity TTM | -51.48% |
Revenue TTM | 7.0M |
Revenue Per Share TTM | 0.96 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -98.5M |
Diluted Eps TTM | -13.12 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.11 |
EPS Estimate Next Year | -8.9 |
EPS Estimate Current Quarter | -3.15 |
EPS Estimate Next Quarter | -3.28 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 93.33%
Technicals Summary
Sell
Neutral
Buy
Kezar Life Sciences Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Kezar Life Sciences Inc | -6.6% | 2.94% | -18.01% | -94.31% | -73.31% |
 Regeneron Pharmaceuticals, Inc. | -21.61% | -24.74% | -7.55% | 13.66% | 101.19% |
 Biontech Se | 1.94% | 14.27% | 14.47% | -63.37% | 445.2% |
 Alnylam Pharmaceuticals, Inc. | -16.95% | 63.94% | 50.31% | 30.85% | 117.83% |
 Vertex Pharmaceuticals Incorporated | -4.06% | 0.04% | 27.74% | 141.35% | 101.98% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Kezar Life Sciences Inc | NA | NA | NA | -2.11 | -0.51 | -0.28 | NA | 25.77 |
Regeneron Pharmaceuticals, Inc. | 18.41 | 18.41 | 1.11 | 44.91 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.04 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -0.17 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.18 | 0.53 | -0.03 | 0.12 | NA | 60.65 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Kezar Life Sciences Inc | Buy | $55.6M | -73.31% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $81.8B | 101.19% | 18.41 | 33.61% |
Biontech Se | Buy | $25.9B | 445.2% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $31.8B | 117.83% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $116.0B | 101.98% | 32.84 | -4.51% |
Insights on Kezar Life Sciences Inc
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 50.3% return, outperforming this stock by 68.1%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 30.9% return, outperforming this stock by 125.2%
Institutional Holdings
Suvretta Capital Management, LLC
98.24%Avidity Partners Management LP
68.89%Vanguard Group Inc
37.57%Sphera Funds Management Ltd.
28.12%Orbimed Advisors, LLC
26.41%Affinity Asset Advisors, LLC
24.15%
Company Information
kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.
Organization | Kezar Life Sciences Inc |
Employees | 58 |
CEO | Dr. Christopher J. Kirk Ph.D. |
Industry | Health Technology |
Discover More
Arc Document Solutions Inc
$7.50
-1.57%
Exscientia Plc
$7.50
-1.57%
Tmt Acquisition Corp
$7.50
-1.57%
Ngl Energy Partners Lp
$7.50
-1.57%
Ondas Holdings Inc
$7.50
-1.57%
Sonida Senior Living Inc.
$7.50
-1.57%
Vitesse Energy Inc.
$7.50
-1.57%
Spdr Marketaxess Investment Grade 400 Corp Bd Etf
$7.50
-1.57%
Blackrock High Yield Bond Etf
$7.50
-1.57%